Most platforms restrict this category more than teams expect.
Pharmaceutical paid media planned around the advertising restrictions the category genuinely operates under: what most ad platforms allow for prescription products, what consumer health can run, and where the real opportunity sits once those limits are accounted for.
Prescription drug advertising is restricted or prohibited on most major platforms in most markets, and teams frequently discover that after a campaign is planned rather than before. Understanding what is genuinely available by product category and market is the first job, before any media plan.
An assessment of what is actually available to advertise by product category and market, campaign strategy within those limits, media planning and buying, and measurement honest about tracking constraints.
We check what platform policy and advertising regulation actually allow for your product category and market before planning any campaign, and we say so upfront when something is not achievable rather than attempting a workaround that gets pulled later.
The scope our pharmaceutical paid media work has operated within.
The restriction level differs sharply by what is being sold. Pharmaceutical paid media starts from that category.
What comes up before committing a paid media budget.
In most cases and most markets, no, or only within narrow limits — both platforms restrict prescription drug advertising significantly. We check the specific rules for your product and market before proposing anything, rather than after a campaign is built.
It depends on category and market, but frequently disease-awareness content, corporate and unbranded campaigns, or consumer health products fall within what platforms and regulators allow. We map the real, permitted options for your specific product and market combination before building any media plan, rather than assuming a standard set of channels applies.
That sits under a distinct discipline with its own verification requirements, since reaching clinicians reliably depends on professional-registry checks that consumer ad platforms cannot perform. We run it as a separate service built around HCP-specific ad networks rather than an extension of consumer paid media. See programmatic HCP advertising for how targeting and verification work there.
We measure it within whatever consent and platform limitations apply, using the aggregate and cohort-level data that remains available under those restrictions. Reporting is explicit about what can and cannot be attributed at an individual level, so decisions are made on data we can stand behind, not an inflated estimate.
Paid media pairs with conversion and analytics work. These are the related services.
A campaign idea you are not sure is achievable, or a budget with nowhere clear to spend it yet. Tell us the product category and we will tell you what pharmaceutical paid media is actually available to you.